THE agenda for the November
meeting of the Pharmaceutical
Advisory Committee (PBAC) is now
available for scrutiny by interested
stakeholders and input is invited.
Some of the drugs being
considered for changes to their
status include oxycodone with
nalaxone for severe disabling pain,
omalizumab for urticaria, irinotecan
for metastatic pancreatic cancer,
Edoxaban anticoagulant and many
more.The above article was sent to subscribers in Pharmacy Daily's issue from 26 Aug 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 26 Aug 16
THE Senate’s Community Affairs Legislation Committee is holding a two-day inquiry into the Therapeutic Goods and Other Legislation Amendment (Vaping Reforms) Bill 2024, which is currently under discussion in Federal Parliament.
A NEW study from the University of South Australia has discovered that an increased cardio-fitness level will reduce risk of death from any cause by nearly 20%.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.